Delaware
|
|
000-50644
|
|
77-0492262
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
|
Description
|
|
Press Release of Cutera, Inc. dated as of August 2, 2010.
|
|
|
CUTERA, INC.
|
||
Date: August 2, 2010
|
|
|
/s/ KEVIN P. CONNORS
|
|
|
|
Kevin P. Connors
|
||
|
|
President and Chief Executive Officer
|
CUTERA, INC.
|
||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS
|
||||||||||||
(in thousands)
|
||||||||||||
(unaudited)
|
||||||||||||
June 30,
|
March 31,
|
December 31,
|
||||||||||
2010
|
2010
|
2009
|
||||||||||
Assets
|
||||||||||||
Current assets:
|
||||||||||||
Cash and cash equivalents
|
$ | 31,697 | $ | 22,519 | $ | 22,829 | ||||||
Marketable investments
|
60,317 | 73,733 | 76,780 | |||||||||
Accounts receivable, net
|
3,824 | 3,488 | 3,327 | |||||||||
Inventories
|
6,955 | 6,953 | 6,408 | |||||||||
Deferred tax asset
|
185 | 178 | 175 | |||||||||
Other current assets and prepaid expenses
|
3,020 | 3,190 | 2,785 | |||||||||
Total current assets
|
105,998 | 110,061 | 112,304 | |||||||||
Property and equipment, net
|
708 | 796 | 847 | |||||||||
Long-term investments
|
7,115 | 7,153 | 7,275 | |||||||||
Intangibles, net
|
733 | 781 | 829 | |||||||||
Deferred tax asset, net of current portion
|
97 | 97 | 97 | |||||||||
Total assets
|
$ | 114,651 | $ | 118,888 | $ | 121,352 | ||||||
Liabilities and Stockholders' Equity
|
||||||||||||
Current liabilities:
|
||||||||||||
Accounts payable
|
$ | 1,495 | $ | 1,898 | $ | 1,081 | ||||||
Accrued liabilities
|
5,922 | 7,328 | 9,048 | |||||||||
Deferred revenue
|
5,898 | 6,270 | 6,160 | |||||||||
Total current liabilities
|
13,315 | 15,496 | 16,289 | |||||||||
Deferred rent
|
1,303 | 1,398 | 1,493 | |||||||||
Deferred revenue, net of current portion
|
1,373 | 1,594 | 1,968 | |||||||||
Income tax liability
|
732 | 729 | 749 | |||||||||
Total liabilities
|
16,723 | 19,217 | 20,499 | |||||||||
Stockholders’ equity:
|
||||||||||||
Common stock
|
14 | 13 | 13 | |||||||||
Additional paid-in capital
|
88,189 | 86,150 | 85,248 | |||||||||
Retained earnings
|
11,475 | 15,236 | 17,254 | |||||||||
Accumulated other comprehensive loss
|
(1,750 | ) | (1,728 | ) | (1,662 | ) | ||||||
Total stockholders’ equity
|
97,928 | 99,671 | 100,853 | |||||||||
Total liabilities and stockholders’ equity
|
$ | 114,651 | $ | 118,888 | $ | 121,352 |
CUTERA, INC.
|
||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
||||||||||||
(in thousands, except per share data)
|
||||||||||||
(unaudited)
|
||||||||||||
Three Months Ended
|
||||||||||||
June 30,
|
March 31,
|
June 30,
|
||||||||||
2010
|
2010
|
2009
|
||||||||||
Net revenue
|
$ | 12,217 | $ | 13,749 | $ | 11,665 | ||||||
Cost of revenue
|
5,335 | 5,829 | 5,130 | |||||||||
Gross profit
|
6,882 | 7,920 | 6,535 | |||||||||
Operating expenses:
|
||||||||||||
Sales and marketing
|
6,452 | 6,361 | 6,071 | |||||||||
Research and development
|
1,506 | 1,454 | 1,495 | |||||||||
General and administrative
|
2,744 | 2,242 | 3,616 | |||||||||
Total operating expenses
|
10,702 | 10,057 | 11,182 | |||||||||
Loss from operations
|
(3,820 | ) | (2,137 | ) | (4,647 | ) | ||||||
Interest and other income, net
|
141 | 166 | 511 | |||||||||
Loss before income taxes
|
(3,679 | ) | (1,971 | ) | (4,136 | ) | ||||||
Provision (benefit) for income taxes
|
82 | 47 | (1,772 | ) | ||||||||
Net Loss
|
$ | (3,761 | ) | $ | (2,018 | ) | $ | (2,364 | ) | |||
Net loss per share:
|
||||||||||||
Basic
|
$ | (0.28 | ) | $ | (0.15 | ) | $ | (0.18 | ) | |||
Diluted
|
$ | (0.28 | ) | $ | (0.15 | ) | $ | (0.18 | ) | |||
Weighted-average number of shares used in per share calculations:
|
||||||||||||
Basic
|
13,501 | 13,438 | 13,317 | |||||||||
Diluted
|
13,501 | 13,438 | 13,317 |
CUTERA, INC.
|
||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||||||
(in thousands)
|
||||||||||||
(unaudited)
|
||||||||||||
Three Months Ended
|
||||||||||||
June 30,
|
March 31,
|
June 30,
|
||||||||||
2010
|
2010
|
2009
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net loss
|
$ | (3,761 | ) | $ | (2,018 | ) | $ | (2,364 | ) | |||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
Stock-based compensation
|
1,761 | 828 | 1,456 | |||||||||
Tax benefit from stock-based compensation
|
- | - | (87 | ) | ||||||||
Depreciation and amortization
|
199 | 194 | 225 | |||||||||
Provision for excess and obsolete inventories
|
109 | (23 | ) | 130 | ||||||||
Provision for doubtful accounts receivable
|
(2 | ) | (82 | ) | 498 | |||||||
Gain on sale of marketable investments, net
|
23 | 43 | - | |||||||||
Change in deferred tax asset
|
(7 | ) | (3 | ) | 139 | |||||||
Changes in assets and liabilities:
|
||||||||||||
Accounts receivable
|
(334 | ) | (79 | ) | 1,936 | |||||||
Inventories
|
(111 | ) | (522 | ) | 1,014 | |||||||
Other current assets and prepaid expenses
|
689 | 252 | (1,053 | ) | ||||||||
Accounts payable
|
(403 | ) | 817 | (408 | ) | |||||||
Accrued liabilities
|
(1,446 | ) | (1,760 | ) | (429 | ) | ||||||
Deferred rent
|
(55 | ) | (55 | ) | (55 | ) | ||||||
Deferred revenue
|
(593 | ) | (264 | ) | (957 | ) | ||||||
Income tax liability
|
3 | (20 | ) | (54 | ) | |||||||
Net cash used in operating activities
|
(3,928 | ) | (2,692 | ) | (9 | ) | ||||||
Cash flows from investing activities:
|
||||||||||||
Acquisition of property and equipment
|
(63 | ) | (95 | ) | (36 | ) | ||||||
Proceeds from sales of marketable and long-term investments
|
14,711 | 14,990 | 9,774 | |||||||||
Proceeds from maturities of marketable investments
|
5,200 | 14,125 | 1,100 | |||||||||
Purchase of marketable and long-term investments
|
(7,021 | ) | (26,712 | ) | (11,342 | ) | ||||||
Net cash provided by (used in) investing activities
|
12,827 | 2,308 | (504 | ) | ||||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from exercise of stock options and employee stock purchase plan
|
279 | 74 | 165 | |||||||||
Net cash provided by financing activities
|
279 | 74 | 165 | |||||||||
Net increase (decrease) in cash and cash equivalents
|
9,178 | (310 | ) | (348 | ) | |||||||
Cash and cash equivalents at beginning of period
|
22,519 | 22,829 | 35,793 | |||||||||
Cash and cash equivalents at end of period
|
$ | 31,697 | $ | 22,519 | $ | 35,445 |
CONSOLIDATED REVENUE HIGHLIGHTS
|
|||||||||||||||
(in thousands, except percentage data)
|
|||||||||||||||
(unaudited)
|
|||||||||||||||
Three Months Ended
|
|||||||||||||||
June 30,
|
% of
|
March 31,
|
% of
|
June 30,
|
% of
|
||||||||||
2010
|
Revenue
|
2010
|
Revenue
|
2009
|
Revenue
|
||||||||||
Revenue By Geography:
|
|||||||||||||||
United States
|
$
|
4,784
|
39%
|
$
|
4,547
|
33%
|
$
|
4,551
|
39%
|
||||||
International
|
7,433
|
61%
|
9,202
|
67%
|
7,114
|
61%
|
|||||||||
$
|
12,217
|
$
|
13,749
|
$
|
11,665
|
||||||||||
Revenue By Product Category:
|
|||||||||||||||
Products (1)
|
$
|
5,676
|
46%
|
$
|
7,445
|
54%
|
$
|
5,142
|
44%
|
||||||
Product upgrades
|
1,338
|
11%
|
1,203
|
9%
|
1,201
|
10%
|
|||||||||
Service
|
3,437
|
28%
|
3,314
|
24%
|
3,397
|
29%
|
|||||||||
Titan refills
|
960
|
8%
|
1,322
|
10%
|
1,403
|
12%
|
|||||||||
Dermal fillers and cosmeceuticals (1)
|
806
|
7%
|
465
|
3%
|
522
|
4%
|
|||||||||
$
|
12,217
|
$
|
13,749
|
$
|
11,665
|
||||||||||
(1) Beginning in 2010, we classified revenue from dermal filler and cosmeceuticals product in the revenue category ‘Dermal filler and cosmeceuticals.’ Previously, we classified these sales in the revenue category ‘Products.’ As such, we reclassified the 2009 revenue from ‘Products’ to ‘Dermal filler and cosmeceuticals.’
|